Lixte Biotechnology Holdings Files 8-K

Ticker: LIXT · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1335105

Lixte Biotechnology Holdings, INC. 8-K Filing Summary
FieldDetail
CompanyLixte Biotechnology Holdings, INC. (LIXT)
Form Type8-K
Filed DateMar 28, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-event, filing, stock

Related Tickers: LIXT

TL;DR

LIXT filed an 8-K on March 27th regarding stock and warrants.

AI Summary

Lixte Biotechnology Holdings, Inc. filed an 8-K on March 28, 2024, reporting an event on March 27, 2024. The filing indicates changes related to common stock and warrants to purchase common stock. The company is incorporated in Delaware and its principal executive offices are located in Pasadena, California.

Why It Matters

This filing signals potential changes in the company's capital structure, which could impact share count and outstanding warrants.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate events and does not immediately indicate significant financial distress or major strategic shifts.

Key Players & Entities

FAQ

What specific event occurred on March 27, 2024, that necessitated this 8-K filing?

The filing indicates an event occurred on March 27, 2024, related to common stock and warrants, but the specific details of the event are not elaborated in the provided text.

What is the Commission File Number for Lixte Biotechnology Holdings, Inc.?

The Commission File Number for Lixte Biotechnology Holdings, Inc. is 001-39717.

Where are Lixte Biotechnology Holdings, Inc.'s principal executive offices located?

The principal executive offices of Lixte Biotechnology Holdings, Inc. are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.

What is the IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc.?

The IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc. is 20-2903526.

What is the state of incorporation for Lixte Biotechnology Holdings, Inc.?

Lixte Biotechnology Holdings, Inc. is incorporated in Delaware.

Filing Stats: 372 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-03-27 19:51:37

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 27, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan President and Chief Executive Officer 3 INDEX TO EXHIBITS Exhibit No. Description 99.1 Press release announcing the publication of pre-clinical data on the effect of Lixte's lead compound, LB-100, on cancer cells 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing